PATENT CLAIM ANALYSIS

Application Number: 15963535
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "210200"]

Abstract:
The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

Claim (Index 1):
A compound of formula (I) wherein E is selected from N and CR E ; R 1 , R 2  and R E  are independently selected from H, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, C 1-4  haloalkoxy, C 1-4  hydroxyalkyl and C 3-7  cycloalkyl; R 3  is selected from (i) C 1-4  alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkyl, oxo, CN, \u2014(C 0-3  alkyl)-NR 3a R 3b , C 3-7  cycloalkyl and C 3-7  heterocyclyl, and wherein the C 3-7  cycloalkyl or C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (ii) C 1-4  alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkyl, oxo, CN, \u2014(C 0-3  alkyl)-NR 3a R 3b , C 3-7  cycloalkyl and C 3-7  heterocyclyl, and wherein the C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (iii) C 3-7  cycloalkyl or \u2014O\u2014C 3-7  cycloalkyl wherein the C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (iv) a \u2014(C 0-3  alkyl)-C 3-7  cycloalkyl or \u2014O\u2014(C 0-3  alkyl)-C 3-7  cycloalkyl wherein the C 3-7  cycloalkyl is spiro fused to a second C 3-7  cycloalkyl or C 3-7  heterocyclyl by one single carbon atom, and wherein the C 3-7  cycloalkyl or C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (v) a \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl or \u2014O\u2014(C 0-3  alkyl)-C 3-7  heterocyclyl, and wherein said C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (vi) a \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl or \u2014(O\u2014C 0-3  alkyl)-C 3-7  heterocyclyl, and wherein said C 3-7  heterocyclyl is spiro fused to a second C 3-7  heterocyclyl or a C 3-7  cycloalkyl by one single carbon atom, and wherein the C 3-7  heterocyclyl or C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (vii) H; R 4  is selected from H and C 1-4  alkyl; or R 3  and R 4  together with the nitrogen atom to which they are attached form a C 3-7  heterocyclyl, which C 3-7  heterocyclyl is optionally spiro fused to a second C 3-7  heterocyclyl or a C 3-7  cycloalkyl by one single carbon atom, and which C 3-7  heterocyclyl and C 3-7  cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; R 3a  and R 3b  are independently selected from H, C 1-4  alkyl and C 1-4  haloalkyl; Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4  alkyl, C 1-4  haloalkyl, C 1-4 alkoxyC 1-4 alkyl, C 1-4 hydroxyalkyl, C 1-4  alkoxy, C 1-4  haloalkoxy, halogen, C 1-4  hydroxyalkyl, \u2014(C 0-3  alkyl)-NR\u2032R\u2033, \u2014(C 0-3  alkyl)-C 3-7  cycloalkyl and \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl, \u2014(C\u2550O)\u2014C 3-7  heterocyclyl, \u2014(C\u2550O)\u2014NR\u2032R\u2033, \u2014(C 0-3  alkyl)-phenyl and \u2014(C 0-3  alkyl)-5-6-membered heteroaryl; R\u2032 and R\u2033 are independently selected from H and C 1-4  alkyl; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.35714
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15303879', '15303868', '15303890', '12765904', '15736450']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8237902180721645
- 35 USC 102 Novelty (BERT): 0.6133208294302728
- Combined Prediction Score: 0.8027432792079753
- Mean Citation Score: 436.623092
- Max Citation Score: 539.0702
- Similarity Product: 523.7431570315362

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test